Keith Meister Sells 75,951 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 75,951 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $218.23, for a total transaction of $16,574,786.73. Following the transaction, the director owned 889,851 shares in the company, valued at $194,192,183.73. This trade represents a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Illumina Stock Down 1.6%

ILMN stock traded down $3.44 during mid-day trading on Friday, hitting $218.22. 1,728,019 shares of the company were exchanged, compared to its average volume of 1,904,505. The firm has a fifty day simple moving average of $197.58 and a 200 day simple moving average of $158.61. The company has a market capitalization of $32.95 billion, a PE ratio of 40.71, a price-to-earnings-growth ratio of 3.02 and a beta of 1.46. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the business posted $1.19 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
• Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
• Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
• Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
• Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Analysts Set New Price Targets

A number of research analysts have commented on the company. Royal Bank Of Canada increased their target price on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a report on Thursday, May 14th. Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a research report on Monday. JPMorgan Chase & Co. raised their price objective on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Barclays lifted their price objective on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a report on Friday, July 31st. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $191.31.

Institutional Investors Weigh In On Illumina

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Illumina in the 2nd quarter worth about $3,374,423,000. Plato Investment Management Ltd acquired a new stake in shares of Illumina in the second quarter valued at approximately $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Illumina in the second quarter valued at approximately $30,501,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Illumina during the second quarter valued at approximately $129,792,000. Finally, Impact Partnership Wealth LLC raised its holdings in shares of Illumina by 235.8% during the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after buying an additional 7,780 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.